Potential of azoximere bromide for treatment of patients with acute inflammatory and infectious upper respiratory diseases

Aim. To evaluate the efficacy and safety of Polyoxidonium® in patients with inflammatory and infectious upper respiratory diseases in real clinical practice. Materials and methods. This retrospective multicenter study included data from adults and children over 6 months old with inflammatory and infectious upper respiratory diseases (n=16 365). The exploratory endpoints included: the proportion of patients with complete relief of symptoms, demographic characteristics of patients, the frequency of prescriptions of Polyoxidonium® by disease groups, determination of the groups of concomitant drugs, most commonly prescribed treatment regimen, frequency of prescribing different Polyoxidonium® dosage forms, duration of the most common specific symptoms of acute respiratory infections during therapy, the incidence of treatment-related adverse events. Results. After treatment completion, the proportion of patients with complete relief of symptoms was 40%, with positive dynamics – 99.77%. Polyoxidonium® in combination therapy was also effective in the treatment of COVID-19 and Post-COVID-19 syndrome. The median patient age was 28 years. Polyoxidonium® was most frequently prescribed for the treatment of inflammatory and infectious upper respiratory diseases in combination with antibiotics or symptomatic drugs in dosage form solution. The primary routes of administration were intranasal and sublingual. The resolution of infection symptoms occurred predominantly within the first 5 days after the initiation of therapy. The therapy appeared to be equally effective across all age groups. No Polyoxidonium®-related adverse events occurred. Conclusion. Treatment with Polyoxidonium® contributes to achieving favorable outcomes in patients with inflammatory and infectious upper respiratory diseases. The study drug has a high safety profile

Radical correction of double outlet of right ventricle with conduits

The use of an artificial pulmonary arterial trunk in the radical correction of complicated congenital heart disease (CHD), such as double origin of the great vessels (DOGV) from the right ventricle (RV) concurrent with pulmonary stenosis is the operation of choice in the presence of anomalous origin of coronary arteries. In 1990 to 2000, the Department of Surgical Treatment of CHD in Old Children, A.N. Bakulev Research Center of Cardiovascular Surgery, Russian Academy of Medical Sciences, repaired the RV outflow tract in 10 patients during radical correction by using an extrac-ardiac conduit. The patients' age ranged from 5 to years (mean, 9,2 ± 2,4 years). Two dacron prostheses were implanted, one of them had a xenoaortic valve. Teflon, vitaflon, and Gore-Tex conduits were used in 2,2, and 2 patients, respectively. A xenopericardial two-flap monoleaflet conduit was employed in 2 cases. In most cases, there was a significant RV pressure reduction that averaged 55,2 ± 14,7 mm Hg. If transannular plasty of the RV outflow tract and the pulmonary artery cannot be performed by means of a flap, the use of conduits provides an adequate repair of the RV outflow tract and considerably enhances life quality in patients